JAKs Are Better? Oral Inhibitors Could Beat Injected Biologics In RA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Buzz over data from trials with Janus-associated kinase inhibitors at the American College of Rheumatology meeting is heating up the debate over whether the class will ultimately beat injected biologics in rheumatoid arthritis
You may also be interested in...
Incyte JAK Inhibitor Shows Promising One-Month Data In Rheumatoid Arthritis
Phase IIb RA studies launch later this year; myelofibrosis update set for December ASH meeting.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.